Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Hidayat R., Diafiri D., Zairinal R.A., Arifin G.R., Azzahroh F., Widjaya N., Fani D.N., Mesiano T., Kurniawan M., Rasyid A., Giantini A., Haris S.
57225289998;57369144600;57214092762;57221703744;57219418635;57424739100;57424721100;57204830976;57196001182;56703146700;12776781400;57222343545;
Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indone-sia: Case Series
2021
Current Neurovascular Research
18
3
360
363
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Universitas Indonesia Hospital, Universitas Indone-sia, Depok, Indonesia
Hidayat, R., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Universitas Indonesia Hospital, Universitas Indone-sia, Depok, Indonesia; Diafiri, D., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Universitas Indonesia Hospital, Universitas Indone-sia, Depok, Indonesia; Zairinal, R.A., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Universitas Indonesia Hospital, Universitas Indone-sia, Depok, Indonesia; Arifin, G.R., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Azzahroh, F., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Widjaya, N., Universitas Indonesia Hospital, Universitas Indone-sia, Depok, Indonesia; Fani, D.N., Universitas Indonesia Hospital, Universitas Indone-sia, Depok, Indonesia; Mesiano, T., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Kurniawan, M., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rasyid, A., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Giantini, A., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Universitas Indonesia Hospital, Universitas Indone-sia, Depok, Indonesia; Haris, S., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Background: Coronavirus disease-19 (COVID-19) is an infectious disease with high morbidity and mortality rates. Indonesia had reported a 2.8% of mortality rate up to June 2021. Case Presentation: A strategy to control the virus spreading is by vaccination. The Indonesian Food and Drug Monitoring Agency had approved the use of CoronaVac, an inactivated virus vaccine developed by Sinovac. Most Adverse Events Following Immunization (AEFI) for Corona-Vac are mild, and the most common symptoms are injection-site pain, headache, and fatigue. Neu-rovascular adverse events, including thrombosis or ischaemic stroke after receiving CoronaVac have not previously been reported. Conclusion: Correspondingly, we reported three patients with an Acute Ischaemic Stroke (AIS) after the administration of CoronaVac in our hospital. © 2021 Bentham Science Publishers.
AEFI; CoronaVac; COVID 19; COVID-19; Stroke; Vaccine
inactivated vaccine; adverse event; aged; brain ischemia; case report; human; incidence; Indonesia; male; middle aged; prevention and control; Aged; COVID-19; COVID-19 Vaccines; Humans; Incidence; Indonesia; Ischemic Stroke; Male; Middle Aged; SARS-CoV-2; Vaccines, Inactivated
Bentham Science Publishers
15672026
34579636
Article
Q3
592
8538